Resumo

CERESETTO, José M. Fibrinolíticos en tromboembolismo de pulmón: Nuevas alternativas para una indicación controvertida. Medicina (B. Aires) [online]. 2018, vol.78, n.4, pp.265-271. ISSN 0025-7680.

The use of fibrinolytics in lung thromboembolism (PTE) is a subject under debate since its first description in the 1960s. This therapy, which can rapidly resolve the mechanical obstruction in the pulmonary artery, has the limiting of a high hemorrhagic risk. Precisely because of the prohibitive incidence of major and cerebral bleeding and the lack of benefit in survival, the use of systemic thrombolytics is only indicated in the small number of patients with severe PE and hemodynamic instability. In moderate-risk PE, even with right ventricular (RV) dysfunction, they are not indicated. In recent years, an alternative has arisen, by combining low doses of fibrinolytics released locally into the pulmonary artery through a catheter that may, or may not, be attached to ultrasound at the site of thrombosis. This way of administering thrombolytics can correct acute pulmonary hypertension and eliminate the thrombus without major or CNS bleeds. Although the published studies are very encouraging, the evidence is still poor, a laboratory of hemodynamics is required at all times and this procedure is not free of risks, with a considerable cost. At the moment, only a small number of patients with moderate PE and poor prognosis seem to have an indication for this new alternative.

Palavras-chave : Fibrinolytics; Pulmonary thromboembolism; Hemorrhagic risk; Catheter.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )